UK Public Sector Contracts & Tenders

MDC is in the market for a supplier to become our digital website agency partner to support our activities in reshaping the UK's medicines discovery industry. At Medicines Discovery Catapult, we manage our corporate website and social channels as well as five other websites and social channels for other brands we oversee. We require a digital agency to support with hosting, support and maintenance of our digital landscape. The purpose of being MDC's sole digital website agency is to: Support with hosting and ongoing website maintenance to all websites through dedicated account management style processes, ensuring the site is user-friendly and accessible. Provide ad-hoc website improvements/development (front and back-end) on a project basis, which will be briefed, resourced, and cost separately from the support, hosting, and maintenance agency retainer. Provide ad-hoc SEO improvements and guidance, which will be costed separately from the support, hosting, and maintenance agency retainer. MDC requires the following services - Hosting, Maintenance and Web Development Support.

Medicines Discovery Catapult required a managed detection and response and for an effective EDR tool. The EDR provision was evaluated on the basis of Mean Time to Detect (MTTD), ease and speed of deployment within the Windows, Mac and Linux estate, detection capabilities (as scored by MITRE ATT&CK evaluations). The tender was ran as a competition under the NHS SBS Digital Solutions framework.

Medicines Discovery Catapult (MDC) is invited quotations for the provision of an "out-of-the-box" SaaS platform that provides business intelligence on companies, deals, financials and markets to support business development, strategic decision-making and impact analysis. The platform will be used to identify and analyse both individual companies and groups of similar companies (determined based on search requirements). The platform will help MDC to identify companies and provide global coverage focusing on small and medium enterprises (SMEs) headquartered in North America and Europe.

Service plan to cover Orbitrap Exploris 240 Basic System and FAIMS Pro.

The contract includes the search, headhunting and recruitment of roles within MDC to source senior or specialist staff. The typical scope of roles / vacancies will include, but are not limited to: Board roles CEO C suite Senior Leadership roles across all disciplines Niche / specific roles All of the above to include: Temporary Staff; and Contractors.

On-site maintenance agreement for Molecubes X Cube (CT) & Molecubes B Cube (PET) equipment.

Technical Business Analyst and Data Analyst roles required for ongoing internal efficiency program.

Research data is the primary deliverable of the MDC and it is essential to have an evident and secure way of its documentation. The data will be used to advance internal capability-build and external feefor-service research projects from a diverse set of scientific technologies, including Mass Spectrometry, Imaging, In-vivo Imaging, Complex Cells, Biomarker and Target Engagement & Validation studies. Consistent with MDC's vision of collaborative working, the platform must enable seamless data sharing of refined data for internal and external projects with scientists and institutions. The software's main task is to document analysed research data and to provide evidence of Good Laboratory Practice as well as improving lab productivity and efficiency, by keeping track of data associated with samples, experiments, laboratory workflows, and instruments. MDC does not currently have a commercial ELN as the previous ELN contract ended in July 2021.

Medicines Discovery Catapult (MDC) intends to award a contract for the purchase of a Xenium single-cell spatial transcriptomics/proteomics instrument to 10X Genomics. The purchase of the equipment will be at a value of £220,000, with the possibility for four twelve month extension of warranty periods.

Research data is the primary deliverable of MDC and it is essential to have an evident and secure way of its documentation. The data will be used to advance internal capability-build and external fee-for-service research projects from a diverse set of scientific technologies, including Mass Spectrometry, Imaging, In-vivo Imaging, Complex Cells, Biomarker and Target Engagement & Validation studies. Consistent with MDC's vision of collaborative working, the platform must enable seamless data sharing for internal and external projects with scientists and institutions. The software's main task is to document research data and to provide evidence of Good Laboratory Practice as well as improving lab productivity and efficiency, by keeping track of data associated with samples, experiments, laboratory workflows, and instruments. MDC does not currently have a commercial ELN as the previous ELN contract ended in July 2021. The current means of tracking samples and laboratory consumables is a combination of paper-based documentation and Microsoft spreadsheets. This is no longer fit for purpose as the business expands and diversifies to include work with clinical samples. As such, MDC now requires a robust LIMS with full traceability to ensure that quality is maintained and to readily demonstrate the integrity of work involving clinical samples.

A lean six sigma consultant is required to deliver process improvements, identification of waste reduction, system enhancements and productivity gains.

Animal Study Workflow Software for one year

A lean six sigma consultant is required to deliver process improvements, identification of waste reduction, system enhancements and productivity gains.

MDC required network switches for its main office location as the current switch software goes end of life in December 2025. The current switches are a combination of Mellanox SN2410 (25Gbps/100Gbps) and EdgeCore 4610 and 5812 (1G and 10G respectively) running Cumulus Linux. The SN2410 switches are the Core switches, also servicing servers and storage. The 4610 and 5812 switches are Edge switches servicing clients. These were to include - 2x Core switches for the network and servers - 2x 10Gbps Edge switches - 8x 1Gbps Edge switches - Any required optics for connections to ISPs and interconnections between switches - All required licenses and warranties for a minimum of 3 years. The switches proposed by suppliers must have been from a manufacturer included as 'Leaders' in the Gartner Magic Quadrant for Enterprise Wired and Wireless LAN 2024 - ie. Juniper, HPE Aruba, Extreme, Fortinet, or Cisco.

The PACE programme is looking for an external provider to deliver an 'Enabling Project' in partnership related to early health economic analysis to support our cohort of AMR diagnostic innovation developers from our 2nd PACE funding call.

Purchase of a Hidex AMG Automatic Gamma Counter, internal Sartorius sample balance, sample QR barcode, including installation and training.

Requirement was for Online Webinar and Web Meeting Delivery Services. The services will include management of live and pre-recorded material, event registration and communications, technical facilitation, speaker support, and live event execution. The supplier shall provide end-to-end support for each online event, including but not limited to the following components

MDC's current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers. While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications. These include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes. This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues to grow. SPECT imaging enables biodistribution studies for isotopes that PET cannot support. This opens up new possibilities for molecular imaging and expands our ability to respond to evolving scientific and clinical needs. We have a clear opportunity to address this gap by introducing SPECT and CT capability through the phased procurement of the SPECT Cube module, followed by an upgrade to the advanced SPECT Cube 2.0 platform. This will allow MDC to meet rising diagnostic demand, align with industry standards, and maintain clinical competitiveness.

A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression. Continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.